Samrat Pharma

Which are the latest news on Samrat Pharma?

Why is Samrat Pharmachem Ltd falling/rising?

As of 18-Jul, Samrat Pharmachem Ltd's stock price is at 257.95, showing a slight decrease but a strong performance over the past week and month. Year-to-date, it has outperformed the Sensex, although it has faced significant declines over the past year and three years.

As of 18-Jul, Samrat Pharmachem Ltd's stock price is currently at 257.95, reflecting a slight decrease of 0.1 (-0.04%). Despite this minor decline, the stock has shown a positive performance over the past week, with a return of +1.56%, which is significantly higher than the Sensex's return of +0.75%. Over the past month, the stock has surged by +30.08%, while the Sensex has only increased by +1.29%. <BR><BR>Year-to-date, Samrat Pharmachem Ltd has outperformed the Sensex, with a return of +13.48% compared to the Sensex's decline of -8.30%. However, the stock has faced challenges over the longer term, with a one-year decline of -31.94% and a three-year decline of -45.30%, contrasting with the Sensex's performance in those periods.<BR><BR>Today's trading performance indicates that the stock has outperformed its sector by 1.2%. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally positive trend in the short to medium term. However, there is a notable decrease in investor participation, with delivery volume falling by -29.17% against the 5-day average, which may contribute to the current price decline.<BR><BR>Overall, while the stock has shown strong short-term performance and is trading above key moving averages, the recent drop in delivery volume and the slight decrease in price could indicate a temporary pullback amidst otherwise positive trends.

How big is Samrat Pharma?

As of 10th June, Samrat Pharmachem Ltd has a market capitalization of 65.00 Cr and reported Net Sales of 289.72 Cr with a Net Profit loss of 3.32 Cr over the latest 4 quarters. Shareholder's Funds were 71.80 Cr and Total Assets were 121.49 Cr as of March 2025.

As of 10th June, Samrat Pharmachem Ltd has a market capitalization of 65.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 289.72 Cr. However, it experienced a loss of 3.32 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 71.80 Cr and Total Assets were valued at 121.49 Cr.

Who are in the management team of Samrat Pharma?

The management team of Samrat Pharma includes Lalit Mehta (Chairman & Managing Director), Rajesh Mehta (Director & CFO), Mahendra Pipalia, Samir Kothary, and Renu P Dharod (all Independent Directors), Megh Mehta (Executive Director), and Nishant Kankaria (Company Secretary & Compliance Officer).

The management team of Samrat Pharma includes the following individuals:<BR><BR>1. **Lalit Mehta** - Chairman & Managing Director<BR>2. **Rajesh Mehta** - Director & CFO<BR>3. **Mahendra Pipalia** - Independent Director<BR>4. **Samir Kothary** - Independent Director<BR>5. **Renu P Dharod** - Independent Director<BR>6. **Megh Mehta** - Executive Director<BR>7. **Nishant Kankaria** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Samrat Pharma?

Samrat Pharma's peers include Source Natural, Vineet Laborator, Sunil Healthcare, and others. Management risk varies, with Samrat Pharma rated as Average, while its 1-year return is -41.51%, slightly better than Source Natural's -42.15%.

Peers: The peers of Samrat Pharma are Source Natural, Vineet Laborator, Sunil Healthcare, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, Shelter Pharma, Vasundhara Rasy., JFL Life, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural and Vasundhara Rasy., while Average management risk is found at Samrat Pharma, Asston Pharmaceu, Shelter Pharma, and JFL Life. Below Average management risk is present at Vineet Laborator, Sunil Healthcare, Biofil Chemicals, Vivo Bio Tech, and Ajooni Biotech. Growth is rated as Excellent for JFL Life, Good for Sunil Healthcare and Shelter Pharma, Below Average for Samrat Pharma, Vineet Laborator, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, and Ajooni Biotech, and the rest. Capital Structure is Excellent for Samrat Pharma and Shelter Pharma, Good for Source Natural and Biofil Chemicals, Average for Asston Pharmaceu, and Below Average for Vineet Laborator, Sunil Healthcare, Vivo Bio Tech, Vasundhara Rasy., JFL Life, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vineet Laborator at 58.07%, while the peer with the lowest is Source Natural at -42.15%. Samrat Pharma's 1-year return is -41.51%, which is slightly better than Source Natural's. Additionally, the six-month return is negative for Source Natural, Sunil Healthcare, Vivo Bio Tech, Asston Pharmaceu, Shelter Pharma, and Vasundhara Rasy.

What does Samrat Pharma do?

Samrat Pharmachem Ltd manufactures and sells chemicals in the Pharmaceuticals & Biotechnology industry, operating as a Micro Cap company. As of March 2026, it reported net sales of 72 Cr and a net loss of 2 Cr.

Overview:<BR>Samrat Pharmachem Ltd is engaged in the manufacturing and selling of chemicals within the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on June 16, 1992. In the fiscal year 2003-04, it established a 100% subsidiary named Samrat Remedies Limited to focus on the manufacturing of pharmaceutical bulk drugs and chemicals. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 72 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 65 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.48% <BR>Debt-Equity: 0.06 <BR>Return on Equity: -4.87% <BR>Price to Book: 0.95<BR><BR>Contact Details:<BR>Address: Plot No A2/3445, GIDC Phase IV Ankleshwar Gujarat : 393002 <BR>Tel: 91-2646-220774 <BR>Email: samrat@bom4.vsnl.net.in <BR>Website: http://www.samratpharmachem.com

Are Samrat Pharmachem Ltd latest results good or bad?

Samrat Pharmachem Ltd's latest results are concerning, reporting a net loss of ₹2.04 crores in Q4 FY26, a 410% decline year-on-year, with negative operating margins and four consecutive quarters of losses, indicating severe operational distress.

The latest results for Samrat Pharmachem Ltd are concerning. In the fourth quarter of FY26, the company reported a net loss of ₹2.04 crores, which is a significant decline of 410% year-on-year. This marks the worst quarterly performance on record for the company. While revenue showed a slight increase of 0.80% year-on-year, reaching ₹71.77 crores, this growth is overshadowed by a catastrophic drop in profitability.<BR><BR>The operating margin turned negative at -1.73%, a stark contrast to the positive margins reported in previous years. Additionally, the profit before tax fell to negative ₹1.87 crores from negative ₹0.36 crores in the same quarter last year. The PAT margin also deteriorated sharply to -2.84% from -0.56% a year earlier.<BR><BR>Overall, the financial performance indicates severe operational distress, with four consecutive quarters of losses and a significant erosion of profitability. Given these results, it can be concluded that the latest performance of Samrat Pharmachem Ltd is quite bad, raising serious concerns about its future viability and operational stability.

Is Samrat Pharma overvalued or undervalued?

As of November 18, 2025, Samrat Pharma is considered overvalued with a PE Ratio of 53.48, significantly higher than its peers, and has experienced a poor year-to-date return of -29.33%, indicating a shift in market perception from very attractive to very expensive.

As of 18 November 2025, the valuation grade for Samrat Pharma has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 53.48, an EV to EBITDA of 18.52, and a Price to Book Value of 1.18, all of which suggest that the stock is priced at a premium compared to its earnings and assets.<BR><BR>In comparison to its peers, Samrat Pharma's PE Ratio is notably higher than Sun Pharma's 36.56 and significantly exceeds Cipla's more attractive valuation at 22.49. Additionally, while the PEG Ratio stands at 0.00, indicating no growth expectations priced in, other competitors like Divi's Lab show a PEG of 1.96, reflecting a more balanced valuation. The company's recent stock performance has been poor, with a year-to-date return of -29.33%, contrasting sharply with the Sensex's gain of 8.36%, further reinforcing the notion that Samrat Pharma is overvalued in the current market environment.

How has been the historical performance of Samrat Pharma?

Samrat Pharma's historical performance shows fluctuating financial metrics, with net sales rising from INR 137.45 crore in March 2020 to a peak of INR 310.65 crore in March 2023, followed by a decline and slight recovery. Key indicators like operating profit and profit after tax also experienced significant volatility during this period.

Answer:<BR>The historical performance of Samrat Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Samrat Pharma's net sales increased from INR 137.45 crore in March 2020 to INR 285.86 crore in March 2025, with a peak of INR 310.65 crore in March 2023. However, there was a decline in net sales from March 2023 to March 2024, followed by a slight recovery in March 2025. The total operating income mirrored this trend, reaching INR 310.65 crore in March 2023 before dropping to INR 281.58 crore in March 2024 and rebounding to INR 285.86 crore in March 2025. The operating profit (PBDIT) saw significant fluctuations, peaking at INR 24.89 crore in March 2022, then dropping to INR 2.47 crore in March 2024, and recovering to INR 10.24 crore in March 2025. Profit after tax also exhibited volatility, with a high of INR 16.63 crore in March 2023, declining to INR 2.16 crore in March 2024, and then increasing to INR 7.11 crore in March 2025. The company's total assets grew from INR 58.35 crore in March 2020 to INR 121.49 crore in March 2025, while total liabilities remained relatively stable, peaking at INR 121.74 crore in March 2024. Cash flow from operating activities was negative in March 2025 at INR -10 crore, contrasting with a positive cash flow of INR 9 crore in March 2024. Overall, Samrat Pharma's financial performance reflects a mix of growth and challenges over the years.

Should I buy, sell or hold Samrat Pharma?

Who are the top shareholders of the Samrat Pharma?

The top shareholder of Samrat Pharma is Lalit Damodar Mehta, holding 13.97%. Individual investors collectively own 41.58%, while the highest public shareholder is Sangeetha S at 3.27%.

The top shareholders of Samrat Pharma include the promoters, with Lalit Damodar Mehta holding the largest share at 13.97%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sangeetha S, who owns 3.27%. Additionally, individual investors collectively hold 41.58% of the company's shares.

What is the technical trend for Samrat Pharma?

As of June 2, 2025, Samrat Pharma's technical outlook is mildly bearish, driven by bearish signals from moving averages and Bollinger Bands, despite some short-term strength indicated by the KST.

As of 2 June 2025, the technical trend for Samrat Pharma has changed from mildly bullish to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is bearish, suggesting a divergence in time frames. The Bollinger Bands are bearish for both weekly and monthly periods, reinforcing the bearish outlook. Daily moving averages are also bearish, which adds to the negative sentiment. The KST shows a mildly bullish signal on the weekly but remains bullish on the monthly, indicating some strength in the short term. Dow Theory reflects a mildly bearish stance on the weekly, with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands.

When is the next results date for Samrat Pharma?

No Upcoming Board Meetings

Has Samrat Pharma declared dividend?

Yes, Samrat Pharma has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 19, 2024. The dividend yield is 0.28%, and while long-term returns have been positive, short-term performance has shown mixed results.

Samrat Pharma has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.34%, with a dividend return of 0%, resulting in a total return of -13.34%.<BR><BR>Over the past year, the price return was 2.78%, with a dividend return of 0.30%, leading to a total return of 3.08%.<BR><BR>In the 2-year period, the price return was -15.92%, while the dividend return was 0.47%, resulting in a total return of -15.45%.<BR><BR>For the 3-year period, the price return was -26.15%, with a dividend return of 0.80%, culminating in a total return of -25.35%.<BR><BR>In the last 4 years, the price return was 38.41%, with a dividend return of 1.26%, giving a total return of 39.67%.<BR><BR>Over the 5-year period, the price return was 363.67%, with a dividend return of 3.57%, resulting in a total return of 367.24%.<BR><BR>Overall, while Samrat Pharma has declared a dividend, the total returns over various periods show a mixed performance, with significant gains over the long term but negative returns in shorter periods. The dividend yield remains relatively low at 0.28%.